1. Home
  2. PCRX

as 03-25-2025 2:33pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Founded: 2006 Country:
United States
United States
Employees: N/A City: TAMPA
Market Cap: 1.1B IPO Year: 2011
Target Price: $30.67 AVG Volume (30 days): 964.4K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.15 EPS Growth: N/A
52 Week Low/High: $11.16 - $31.67 Next Earning Date: 05-06-2025
Revenue: $700,966,000 Revenue Growth: 3.85%
Revenue Growth (this year): 9.77% Revenue Growth (next year): 9.83%

PCRX Daily Stock ML Predictions

Share on Social Networks: